Cure8 research brief
The study suggests people with Crohn's disease or ulcerative colitis have higher lipoprotein(a) levels than healthy controls, which could be relevant because Lp(a) is a cardiovascular-risk biomarker and cardiovascular risk is an important comorbidity consideration in IBD.
Clinicians (gastroenterologists, primary care, cardiology), researchers on IBD and cardiovascular risk, and adult patients with IBD interested in cardiovascular risk assessment.
This is a systematic review and meta-analysis (abstract level) that searched databases up to Dec 30, 2024 and included 11 studies overall, with 6 studies contributing to the quantitative meta-analysis (1,978 participants total: 1,196 IBD patients and 782 healthy controls).
The pooled results reported higher Lp(a) levels in both Crohn's disease and ulcerative colitis compared with healthy controls. The authors conclude that assessing Lp(a) may be advisable when evaluating IBD patients. The study is presented as an abstract/summary of the meta-analysis; Cure8 has not reviewed the full paper here.
The abstract does not provide details on study-by-study heterogeneity, adjustment for confounders (for example, inflammation, lipid-lowering therapy, or cardiovascular risk factors), or whether increased Lp(a) translated into clinical outcomes.
This entry is based on the article abstract (systematic review and meta-analysis). The abstract reports pooled higher Lp(a) in IBD but does not provide full-methods, adjustment details, or outcome data; consult the full paper for clinical decision-making.
Review the original publication for the complete reporting, methods, and context.
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
The study suggests measurable retinal and choroidal microvascular differences in people with IBD versus controls, which could point to systemic vascular effects of inflammation and offer noninvasive biomarker...
The work identifies a genetic link (HLA‑DRB1*01:03) to anti‑IL‑10 autoantibodies and describes a small subgroup of IBD patients who may have a distinct immune mechanism driving disease—information that could matter for...
FAP appears linked to both inflammation and fibrosis in IBD; distinguishing cellular versus extracellular FAP might help develop or validate fibrosis biomarkers that detect fibrostenotic disease.
